Inhibition of glycolysis in cancer cells: A novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia

Cancer Research

Volumn 65, Issue 2, 2005, Pages 613-621

  Xu, Rui Hua ^a,b   Pelicano, Helene ^a   Zhou, Yan ^a   Carew, Jennifer S ^a   Feng, Li ^a   Bhalla, Kapil N ^c   Keating, Michael J ^a   Huang, Peng ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; PROTEIN BAX;

APOPTOSIS; ARTICLE; CANCER CELL; CELL DEATH; CELL ENERGY; CONTROLLED STUDY; DRUG SENSITIVITY; GLYCOLYSIS; HUMAN; HUMAN CELL; HYPOXIA; MITOCHONDRIAL RESPIRATION; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; RESPIRATORY FAILURE;

ADENOSINE TRIPHOSPHATE; BCL-2-ASSOCIATED X PROTEIN; BCL-ASSOCIATED DEATH PROTEIN; CARRIER PROTEINS; CELL HYPOXIA; CELL RESPIRATION; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GLYCOLYSIS; HL-60 CELLS; HUMANS; MITOCHONDRIA; NEOPLASMS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRUVATES;

EID: 12544256565     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Warburg O. The metabolism of tumors. London: Constable Co. Ltd.; 1930.
2. Warburg O. On the origin of cancer cells. Science 1956;123:309-14.
3. Zu XL, Guppy M. Cancer metabolism: facts, fantasy, and fiction. Biochem Biophys Res Commun 2004;313:459-65.
4. Penta JS, Johnson FM, Wachsman JT. Copeland WC. Mitochondrial DNA in human malignancy. Mutat Res 2001;488:119-33.
5. Carew JS, Huang P. Mitochondrial defects in cancer. Mol Cancer 2002;1:9.
6. Carew JS, Zhou Y, Albitar M, Carew JD, Keating MJ, Huang P. Mitochondrial DNA mutations in primary leukemia cells after chemotherapy: clinical significance and therapeutic implications. Leukemia 2003;17:1437-47.
7. Pelicano H, Carney D, Huang P. ROS stress in cancer cells and therapeutic implications. Drug Resist Updat 2004;7:97-110.
8. Guppy M. The hypoxic core: a possible answer to the cancer paradox. Biochem Biophys Res Commun 2002;299:676-80.
9. Hardie DG. Metabolic control: a new solution to an old problem. Curr Biol 2000;10:R757-9.
10. Seta KA, Spicer Z, Yuan Y, Lu G, Millhorn DE. Responding to hypoxia: lessons from a model cell line. Sci STKE 2002;146:1-16.
11. Mathupala SP, Rempel A, Pedersen PL. Glucose catabolism in cancer cells: identification and characterization of a marked activation response of the type II hexokinase gene to hypoxic conditions. J Biol Chem 2001;276:43407-12.
12. Geschwind JF, Georgiades CS, Ko YH, Pedersen PL. Recently elucidated energy catabolism pathways provide opportunities for novel treatments in hepatocellular carcinoma. Expert Rev Anticancer Ther 2004;4:449-57.
13. Maher JC, Krishan A, Lampidis T. Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-D-glucose in tumor cells treated under hypoxic vs aerobic condition. Cancer Chemother Pharmacol 2004;53:116-22.
14. Maschek G, Savaraj N, Priebe W, et al. 2-Deoxy-D-glucose increases the efficacy of Adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res 2004;64:31-4.
15. Ko YH, Pedersen PL, Geschwind JF. Glucose catabolism in the rabbit VX2 model for liver cancer. Cancer Lett 2001;173:83-91.
16. Geschwind JF, Ko YH, Torbenson MS, Magee C, Pedersen PL. Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production. Cancer Res 2002;62:3909-13.
17. Pelicano H, Feng L, Zhou Y, et al. Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J Biol Chem 2003;278:37832-9.
18. Mone AP, Huang P, Pelicano H, et al. Hu1D10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells. Blood 2004;103:1846-54.
19. Seymour JF, Huang P, Plunkett W, Gandhi V. Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule. Clin Cancer Res 1996;2:653-8.
20. Danial NN, Gramm CF, Scorrano L, et al. BAD and glucokinase reside in a mitochondrial complex that integrates glycolysis and apoptosis. Nature 2003;424:952-6.
21. Cheng EH, Wei MC, Weiler S, et al. BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX-and BAK-mediated mitochondrial apoptosis. Mol Cell 2001;8:705-11.
22. Huang Y, Ibrado AM, Reed JC, et al. Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells. Leukemia 1997;11:253-7.
23. Semenza GL, Artemov D, Bedi A, et al. "The metabolism of tumours": 70 years later. Novartis Found Symp 2001;240:251-60.
24. Unruh A, Ressel A, Mohamed HG, et al. The hypoxia-inducible factor-1α is a negative factor for tumor therapy. Oncogene 2003;22:3213-20.
25. Brown JM, Wilson WR. Exploiting tumor hypoxia in cancer treatment. Nat Rev Cancer 2004;4:437-47.
26. Moeller BJ, Cao Y, Li CY, Dewhirst MW. Radiation activities HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 2004;5:429-41.
27. Erler JT, Cawthorne CJ, Williams KJ, et al. Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance. Mol Cell Biol 2004;24:2875-89.
28. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 1996;87:619-28.
29. Wang X. The expanding role of mitochondria in apoptosis. Genes Dev 2001;15:2922-33.
30. Datta SR, Ranger AM, Lin MZ, et al. Survival factor-mediated BAD phosphorylation raises the mitochondrial threshold for apoptosis. Dev Cell 2002;3:631-43.
31. Leist M, Single B, Castoldi AF, Kuhnle S, Nicotera P. Intracellular adenosine triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis. J Exp Med 1997;185:1481-6.
32. Lelli JL Jr, Becks LL, Dabrowska MI, Hinshaw DB. ATP converts necrosis to apoptosis in oxidant-injured endothelial cells. Free Radic Biol Med 1998;25:694-702.
33. Lieberthal W, Menza SA, Levine JS. Graded ATP depletion can cause necrosis or apoptosis of cultured mouse proximal tubular cells. Am J Physiol 1998;274:F315-27.
34. McConkey DJ. Biochemical determinants of apoptosis and necrosis. Toxicol Lett 1998;99:157-68.
35. Cole SP, Bhardwaj G, Gelach JH, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992;258:1650-4.
36. Tan B, Piwnica-Worms D, Ratner L. Multidrug resistance transporters and modulation. Curr Opin Oncol 2000;12:450-8.
37. Pedersen PL, Mathupala S, Rempel A, et al. Mitochondrial bound type II hexokinase: a key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention. Biochim Biophys Acta 2002;1555:14-20.